GGHC
ITCI

Gilder Gagnon Howe & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-300,952
Closed -$11.7M – 289
2016
Q2 		$11.7M Buy
300,952
+9,620
+3% +$346K 0.23% 80
2016
Q1 		$8.1M Sell
291,332
-7,091
-2% -$236K 0.16% 91
2015
Q4 		$16.1M Sell
298,423
-3,233
-1% -$163K 0.26% 72
2015
Q3 		$12.1M Buy
+301,656
New +$9.84M 0.19% 90

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Gilder Gagnon Howe & Co's ITCI Position: Q3 2016 in Review

Gilder Gagnon Howe & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 300,952 shares — an estimated $11.7M sold.

Gilder Gagnon Howe & Co first reported a position in ITCI in Q3 2015 and held it in 4 quarters. The position peaked at $16.1M in Q4 2015. 132 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • Gilder Gagnon Howe & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 300,952 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $11.7M.
  • Gilder Gagnon Howe & Co first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's Intra-Cellular Therapies Inc. position peaked at $16.1M in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2016, filed 1 Nov 2016.